Tagged with UK

UK Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and private sector and Cobra Biologics’ ambitious plans for 2022. Can you please introduce Cobra Biologics to our international readers? “The…

Innovation The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed by Moorfields eye hospital, University College London and Google’s DeepMind can identify over 50 eye diseases with 94% accuracy. Among the diseases…

UK Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James Noble, shares Adaptimmune’s story and explains why regulatory support is essential in a field as complex and novel as T-Cell…

UK Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse stakeholder groups, improving outcomes for UK patients.   We do see a will and an intent from stakeholders, from government…

UK With a strong historic footprint in Edinburgh, Canon Medical Systems has based one of its global R&D centres in Scotland from where it develops software for its devices. Ken Sutherland, president, explains how Canon is able to leverage on the talent available in Scotland and what trends he is observing…

UK After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR T therapies towards the clinic. Developing allogeneic variants of Gamma Delta T Cells, TC BioPharm aims to become a global…

UK Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and global leadership in clinical trials. To her, the UK has to maintain its core differentiators, such as a health technology…

UK Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role outside of North America, discusses the creation of new, innovative partnership models with stakeholders across the healthcare spectrum, how Amgen is leveraging its biologic…

UK Geoff Twist, managing director of Roche Diagnostics UK and Ireland, analyses the changing mindset he sees at various levels, leaning towards greater recognition of pathology’s impact on health systems. He further highlights some exciting paths Roche Diagnostics is embarking on, such as digital pathology and widened molecular screening programmes. After…

UK Peter Burema, CEO of NextPharma, explains the specificities of a UK-based CDMO with manufacturing sites on the European continent. He describes how NextPharma refocused its efforts on being a customer-centric one-stop-shop by deciding on smart investments, and why quality will always remain the key differentiation factor for a CDMO. In…

UK Laura McMullin, General Manager of the pharmaceutical division of Pierre Fabre in the UK and Ireland, explains the huge untapped potential of the organisation and her intention to make the affiliate the best performing in the coming years. She also details the strong heritage of Oncology and the affiliate’s exciting…

UK With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE, highlights what else makes the region special: its great talent, dedication to discovery and ability to build bridges between academia…